Form 4: Revolution Medicines Exec Acquires Shares, Options

Revolution Medicines' President of Research and Development, Stephen Michael Kelsey, acquired 21,100 shares of common stock and 47,600 stock options.

Summary

• Stephen Michael Kelsey, President, Research and Development at Revolution Medicines, Inc. (RVMD), reported transactions in company securities.
• Acquired 21,100 shares of common stock on March 1, 2026, at a price of $0, likely indicating a grant.
• Beneficial ownership of common stock following this transaction is 299,700 shares, which includes 94,676 restricted stock units.
• Acquired 47,600 stock options (right to buy) on March 1, 2026, with an exercise price of $102.02.
• These stock options will vest at a rate of one forty-eighth (1/48th) of the shares monthly, commencing from March 1, 2026, and will be fully vested on the fourth anniversary of this date, subject to continued service.
• The acquired stock options have an expiration date of February 28, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting the company's commitment to retaining and incentivizing a key R&D executive through equity compensation, aligning his interests with long-term shareholder value.

Positives

• Executive Stephen Michael Kelsey acquired 21,100 shares of common stock, which can signal alignment of management's interests with shareholder value.
• The grant of 47,600 stock options with a four-year vesting schedule incentivizes long-term commitment and performance from a key Research and Development executive.

Future Outlook

The vesting schedule for the 47,600 stock options, which extends over four years from March 1, 2026, implies an expectation of Stephen Michael Kelsey's continued service and contribution to Revolution Medicines' long-term objectives, particularly in Research and Development.

Industry Context

StockSavvy.ai notes that executive equity grants, such as those reported in this Form 4, are a standard component of compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align executive incentives with long-term shareholder value creation, particularly for key R&D personnel like Stephen Michael Kelsey, whose expertise is critical to drug development success.

Stakeholder Impact

• Shareholders: The acquisition of shares and options by a key executive can be viewed positively as it aligns management's interests with shareholder value creation and incentivizes long-term performance.

Next Steps

• Vesting of 47,600 stock options over the next four years, contingent on Stephen Michael Kelsey's continued service to Revolution Medicines.

Key Dates

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, Insider transaction, Stock option, Common stock, Executive compensation, SEC Form 4, Equity grant, Restricted stock units